The success of SARS-CoV-2 vaccines and challenges ahead
2021/07/01 by Kanta Subbarao · 1 citation
Medicine · #COVID-19 Clinical Research Studies #Influenza Virus Research Studies #SARS-CoV-2 and COVID-19 Research
paper · pdf · doi:10.1016/j.chom.2021.06.016
crossref issued 2021/07/01 · crossref published 2021/07/01 · crossref published-print 2021/07/01 · openalex publication_date 2021/07/01 · crossref created 2021/07/14 · openalex created_date 2025/10/10 · crossref deposited 2025/10/30 · crossref indexed 2026/07/18 · openalex updated_date 2026/07/28
Citations
- Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
- A new coronavirus associated with human respiratory disease in China
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
- SARS-CoV-2 vaccines in development
- Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Cited by